NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN.

· Circio plans to raise around NOK 50-60 million in gross proceeds in a
partially underwritten rights issue to be completed during Q2 2024
  · The intended financing will provide twelve months of runway, enabling
delivery of key circVec circular RNA platform milestones
  · Members of CircioŽs board and management have pre-committed to participate
with around NOK 2 million in the fundraising
  · Atlas Capital Markets is supportive of, and intends to participate in, the
financing
  · Redeye AB is acting as financial advisor to Circio

Oslo, Norway 17 April 2024 - Circio Holding ASA (OSE: CRNA, "Circio"), a
biotechnology company developing next generation circular RNA vector technology
for gene therapy, announces that it is initiating a fundraising process with the
intent to raise around NOK 50-60 million or more in gross proceeds from existing
shareholders and new investors in a partially underwritten rights issue to be
completed during Q2 2024.

"The board strongly believes in the potential of CircioŽs unique circVec
platform, and this intended fundraising will provide the company with the
required capital to validate the significant advantage of the technology in gene
therapy," said Damian Marron, Chairman of Circio. "With twelve months runway,
Circio will have time to reach important R&D milestones and will aim to achieve
its first business development deal, thereby delivering value to our
shareholders."

Existing convertible bond investor Atlas Capital Markets is supportive of, and
intends to participate in, the intended fundraising. Members of CircioŽs board
and management have pre-committed to participate with around NOK 2 million,
including NOK 500.000 by CEO Dr. Erik D Wiklund.

"Circio has now demonstrated technical validation for its circVec circular RNA
platform both in vitro and in vivo and is pushing ahead to establish in vivo
proof-of-concept for its novel circVec gene therapy formats," said Dr. Erik
Digman Wiklund, CEO at Circio. "This financing will enable Circio to develop the
lead program in AATD towards selection of a lead therapeutic candidate by the
middle of next year. In parallel, Circio will continue to improve and expand the
circVec platform, which will open opportunities for multiple future revenue
-generating partnerships both in the short- and long-term."

Circio will update the market in due time when the structure and timing of the
intended transaction have been determined.

Redeye AB will be acting as financial advisor to Circio and sole bookrunner in
the transaction and Advokatfirmaet Thommessen AS is acting as legal advisor.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com (erik.wiklund@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

Important notice:

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. The
distribution of this announcement and other information may be restricted by law
in certain jurisdictions. Copies of this announcement are not being made and may
not be distributed or sent into any jurisdiction in which such distribution
would be unlawful or would require registration or other measures. Persons into
whose possession this announcement or such other information should come are
required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering or their
securities in the United States or to conduct a public offering of securities in
the United States. Any sale in the United States of the securities mentioned in
this announcement will be made solely to "qualified institutional buyers" as
defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at (i) qualified investors in that Member State within the meaning of
the Prospectus Regulation, and (ii) to fewer than 150, natural or legal persons
, subject to obtaining the prior consent of the Company for any such offer,
i.e., only to investors who can receive the offer without an approved prospectus
in such EEA Member State. The expression "Prospectus Regulation" means
Regulation 2017/1129 as amended together with any applicable implementing
measures in any Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom who are qualified investors within the meaning of Article
2(1)(e) of the Prospectus Regulation, as the term is used in Article 1(4) and
(6) of the Prospectus Regulation, that are also (i) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the Order) or (ii) high net worth
entities, and other persons to whom this announcement may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all such
persons together being referred to as Relevant Persons). This communication must
not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this communication relates is
available only for relevant persons and will be engaged in only with relevant
persons.

Persons distributing this communication must satisfy themselves that it is
lawful to do so.

The information contained in this announcement speak only as at its date, and
are subject to change without notice. The Company does not undertake any
obligation to review, update, confirm, or to release publicly any revisions to
any of the content of this announcement.

The Company makes no representation as to the accuracy or completeness of this
announcement and does not accept any responsibility for the contents of this
announcement or any matters referred to herein. This announcement is for
information purposes only and is not to be relied upon in substitution for the
exercise of independent judgment. It is not intended as investment advice and
under no circumstances is it to be used or considered as an offer to sell, or a
solicitation of an offer to buy any securities or a recommendation to buy or
sell any securities in the Company. The Company accepts no liability arising
from the use of this announcement.

This information is subject to a duty of disclosure pursuant to the Company's
continuing obligations as a company listed on the Oslo Stock Exchange. This
information was issued as inside information pursuant to the EU Market Abuse
Regulation, and was published by Mats Hermansen, VP Finance of Circio, on the
date and time set out above.